McGill Blood Clotting Breakthrough: Researchers Develop Life-Saving Click Clotting Method

Researchers at McGill University have unveiled a groundbreaking advancement in hemostasis, introducing a technique known as click clotting that promises to transform how severe bleeding is managed. This innovative method rapidly engineers blood clots that are not only faster to form but also significantly stronger and more effective at promoting tissue healing. Published in the prestigious journal Nature, the study highlights the potential of bioorthogonal click chemistry to crosslink red blood cells, creating cytogels that integrate seamlessly with the body's natural clotting processes. Led by Professor Jianyu Li from McGill's Department of Mechanical Engineering and Bioengineering, the work addresses a critical gap in emergency medicine where every second counts.

Uncontrolled bleeding remains a leading cause of preventable death in trauma cases across Canada and globally. In Canada alone, injury-related mortality stands at approximately 47 per 100,000 people annually, with trauma accounting for thousands of hospitalizations each year. Traditional blood clots, while essential for stopping blood loss, often form too slowly and lack the mechanical robustness needed for severe injuries, leading to re-bleeding risks and compromised healing. Click clotting changes this paradigm by enabling the creation of engineered blood clots using either a patient's own blood or type-matched donor blood, prepared in as little as 10 to 20 minutes.

The Urgent Challenge of Hemorrhage Control

Hemorrhage, or excessive bleeding, poses an immediate threat in scenarios like car accidents, surgical complications, and combat injuries. In Canada, acute inpatient hospitalizations due to injuries reached 283,000 in the 2023-2024 fiscal year, with bleeding often exacerbating outcomes. Natural hemostasis—the physiological process of clotting—involves a complex cascade: vascular spasm, platelet plug formation, coagulation factors activating thrombin to convert fibrinogen into fibrin, and finally, clot stabilization. However, this can take minutes, during which patients lose critical blood volume.

Current interventions like pressure dressings, tourniquets, or hemostatic agents such as Floseal provide temporary relief but fall short in deep wounds or coagulopathies. Chitosan-based products, derived from shellfish, have been tried but result in brittle clots, cell rupture, and inconsistent performance. McGill's approach sidesteps these issues by leveraging living red blood cells (RBCs), which constitute 40-45% of blood volume, as structural building blocks rather than mere oxygen carriers.

How Click Clotting Works: A Step-by-Step Breakdown

At its core, click clotting employs bioorthogonal click chemistry, a Nobel Prize-winning reaction (2010 Chemistry Nobel for CuAAC, evolved to metal-free variants) that is fast, efficient, and occurs only between specific synthetic groups without interfering with biology. Here's the process:

• Step 1: RBC Surface Modification – RBCs are treated with trans-cyclooctene (TCO), a small molecule that covalently attaches to surface proteins via biocompatible reactions. RBCs lack nuclei or Golgi, making traditional metabolic labeling impossible, so surface chemistry is key.
• Step 2: Polymer Preparation – Hyaluronic acid (HA), a natural extracellular matrix component, is modified with tetrazine (TZ) groups (e.g., HA-TZ variants with 20-60% substitution). HA provides biocompatibility and hydration.
• Step 3: Rapid Crosslinking – TCO-RBCs mix with HA-TZ, triggering inverse electron-demand Diels-Alder reaction (TCO-TZ ligation). Cytogel forms in 5 seconds, a network of crosslinked RBCs.
• Step 4: Integration with Whole Blood – Cytogel added to blood activates natural coagulation, embedding within fibrin for engineered blood clots (EBCs).

This yields a hybrid material where RBCs form a tough scaffold, fibrin fills gaps, enhancing overall mechanics. For more on the chemistry, the original study offers detailed protocols.Nature publication

Mechanical Superiority: Why These Clots Are Tougher

Quantitative tests reveal EBCs' prowess: fracture toughness 13 times higher than native clots, adhesion energy 4 times greater. In lap-shear assays, they bond strongly to tissues, resisting detachment under pressure. Finite element modeling shows cell rupture as the primary toughening mechanism—RBCs sacrifice integrity to dissipate energy, unlike weak fibrin networks.

Cyclic loading demonstrates recovery, with hysteresis indicating energy absorption. 3D imaging confirms a percolating RBC network interpenetrated by fibrin, absent in controls. Burst pressure tests in rat models exceed physiological levels, ensuring hemostasis under arterial flow.

McGill's Innovative Team and Research Ecosystem

Professor Jianyu Li, Canada Research Chair in Tissue Repair and Regeneration, leads a multidisciplinary lab blending mechanics, bioengineering, and medicine. His team includes PhD lead Shuaibing Jiang (now at Harvard), Guangyu Bao, Zhen Yang, and collaborators from UBC's Christian Kastrup lab, U Toronto, and Versiti Blood Research Institute. Funded by CIHR and NFRF-Exploration, this reflects Canada's commitment to translational research.CIHR overview

McGill's Bioengineering Department exemplifies Canadian higher education's strength, ranking among global leaders in biomedical innovation. Such breakthroughs attract talent, fostering jobs in research assistance, postdocs, and faculty roles.

Proven in Animal Models: From Bench to Bleeding Control

In rat liver laceration and tail amputation, EBCs stopped bleeding faster than Floseal, with higher burst pressures. Liver defects healed nearly completely by day 28, with restored albumin levels indicating regeneration. Histology showed minimal inflammation, fibrosis, or adhesions—superior to commercial agents.

Allogeneic EBCs in immune-mismatched rats showed no toxicity, normal serology, and biocompatibility over 28 days. Subcutaneous implants confirmed tissue integration without foreign body reactions. McGill's news release details these visuals.McGill release

Safety Profile: Biocompatible and Versatile

Bioorthogonality ensures no interference with coagulation or immunity. Autologous prep (20 min) suits emergencies; allogeneic (10 min) enables stockpiling. No hemolysis, thrombosis risks low due to triggerable nature. Versatile for cells/polymers, opening doors to platelet gels or stem cell scaffolds.

Applications Expanding Beyond Trauma

While ideal for trauma—where hemorrhage kills 20-40% prehospital—click clotting aids surgery (anti-adhesion), chronic wounds, hemophilia, and von Willebrand disease. In Canada, with 17,000+ injury deaths yearly, it could save lives regionally. Potential in regenerative medicine: cytogels for organoids or drug delivery.

Path to Clinic: Challenges and Next Steps

Preclinical success paves way for trials, but scalability, GMP production, and human variability need addressing. Li envisions in-patient kits. Commercialization via McGill spin-offs aligns with Canada's medtech ecosystem (e.g., MaRS, UBC spin-outs).

Boosting Canadian Higher Education and Research Careers

This Nature publication underscores McGill's prowess, drawing CIHR funds and international collaborators. It highlights opportunities in bioengineering—postdocs, faculty at McGill/UBC/UofT. Canada's research chairs like Li's propel innovation, creating jobs in labs tackling real-world problems. For aspiring researchers, McGill exemplifies interdisciplinary training.GEN coverage

Photo by Brett Jordan on Unsplash

In summary, McGill's click clotting breakthrough redefines hemostasis, blending chemistry, engineering, and biology for life-saving impact. As it advances, expect ripple effects in Canadian universities, fostering a new generation of biomedical innovators.